WallStSmart

Absci Corp (ABSI)vsargenx NV ADR (ARGX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

argenx NV ADR generates 378854% more annual revenue ($5.92B vs $1.56M). ARGX leads profitability with a 31.7% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).

ABSI

Avoid

20

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: -0.85

ARGX

Strong Buy

73

out of 100

Grade: B

Growth: 10.0Profit: 9.5Value: 6.7Quality: 6.0
Piotroski: 3/9Altman Z: 4.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABSISignificantly Overvalued (-65.6%)

Margin of Safety

-65.6%

Fair Value

$1.57

Current Price

$7.51

$5.94 premium

UndervaluedFair: $1.57Overvalued
ARGXUndervalued (+67.1%)

Margin of Safety

+67.1%

Fair Value

$2537.60

Current Price

$925.70

$1611.90 discount

UndervaluedFair: $2537.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABSI1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

ARGX6 strengths · Avg: 10.0/10
Return on EquityProfitability
32.8%10/10

Every $100 of equity generates 33 in profit

Profit MarginProfitability
31.7%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
31.9%10/10

Strong operational efficiency at 31.9%

Revenue GrowthGrowth
52.1%10/10

Revenue surging 52.1% year-over-year

EPS GrowthGrowth
50.6%10/10

Earnings expanding 50.6% YoY

Altman Z-ScoreHealth
4.9210/10

Safe zone — low bankruptcy risk

Areas to Watch

ABSI4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.74B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

ARGX3 concerns · Avg: 3.0/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
172.1x2/10

Trading at 172.1x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : ABSI

The strongest argument for ABSI centers on Debt/Equity.

Bull Case : ARGX

The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 31.9%. Revenue growth of 52.1% demonstrates continued momentum.

Bear Case : ABSI

The primary concerns for ABSI are EPS Growth, Market Cap, Profit Margin.

Bear Case : ARGX

The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.

Key Dynamics to Monitor

ABSI profiles as a value stock while ARGX is a growth play — different risk/reward profiles.

ABSI carries more volatility with a beta of 2.19 — expect wider price swings.

ARGX is growing revenue faster at 52.1% — sustainability is the question.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ARGX scores higher overall (73/100 vs 20/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Absci Corp

HEALTHCARE · BIOTECHNOLOGY · USA

Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes a proprietary AI-driven platform to revolutionize drug discovery and development. By facilitating the rapid generation of high-quality proteins and therapeutic candidates, Absci effectively shortens development timelines and lowers associated costs, establishing itself as a key innovator within the biopharmaceutical sector. The company's robust pipeline, complemented by strategic partnerships, underscores its commitment to advancing next-generation therapies that address critical medical needs and improve patient outcomes.

Visit Website →

argenx NV ADR

HEALTHCARE · BIOTECHNOLOGY · USA

argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.

Want to dig deeper into these stocks?